1. Compared to placebo, monthly garadacimab significantly reduced the number of hereditary angioedema attacks per month. 2. Overall, garadacimab was...

1. Past infection with ancestral, alpha, beta, and delta variants of COVID-19 had a protection rate of approximately 78% against...

1. Patients receiving secukinumab every 2-weeks showed superior clinical response rates compared to those receiving placebo. 2. Secukinumab was well-tolerated,...

1. An oral dose of sebetralstat increased the time to conventional treatment use and lead to faster symptom relief in...

1. After a 24-week treatment period, a significantly greater proportion of patients randomized to momelotinib had symptom scores reduced by...

1. Patients who received adjuvant S-1 had prolonged overall survival and relapse-free survival compared to those who were managed with...

1. Global cure was achieved in 59% of the rezafungin group compared to 61% of the caspofungin group. 2. There...

1. Incidence of total adverse events and specific adverse events were similar between the emraclidine groups and placebo. 2. There...

1. Compared to placebo, participants on aprocitentan had a greater reduction in office systolic blood pressure at four weeks and...

1. Compared to a 9-month injectable-containing (control) regimen, both bedaquiline-containing oral regimens had more favourable outcomes, such as negative cultures....